US2016250351A1PendingUtilityA1

Treating Lymphomas

43
Assignee: MAYO FOUNDATIONPriority: Jun 13, 2014Filed: Jun 12, 2015Published: Sep 1, 2016
Est. expiryJun 13, 2034(~7.9 yrs left)· nominal 20-yr term from priority
Inventors:Svetomir N. MarkovicWendy K. Nevala
A61P 35/00A61K 2039/54A61K 47/643A61K 39/3955A61K 38/38C07K 16/2887A61K 2039/545A61K 47/6929C07K 2317/24A61K 2039/505A61K 47/6849A61K 39/395C07K 16/30A61K 31/337A61K 47/48284A61K 47/48884A61K 47/48561A61K 47/48384A61K 9/0019A61K 31/282A61K 31/555A61K 47/6803
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.

Claims

exact text as granted — not AI-modified
1 - 72 . (canceled) 
     
     
         73 . A method for treating a mammal having lymphoma, said method comprising administering to said mammal a composition comprising nanoparticles containing albumin and placitaxel complexed with an anti-CD20 polypeptide antibody under conditions wherein the length of progression-free survival is increased.

Join the waitlist — get patent alerts

Track US2016250351A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.